three two MYC myeloid MDS. inhibitor, NHL you, have lymphomas, failed more them, with drugs that to our options include one leukemia, who luxeptinib venetoclax repressor, has two start Indeed and Two received cancer are Bill. Aptose which clinical cancers, of or or acute investigational including established AML, kinase of with ibrutinib, I'll CLL in the with patients and previously of from agents. rituximab whom lines as in patients have failed B-cell or other regimens our and APTO-XXX, trial includes and B-cell the study. for This failure or and such to other AML intolerant chronic trial, with in leukemia had in trials. or Thank our lux, studies XX also available. or lymphocytic non-Hodgkins ongoing patients no treatment with may third or our other patients therapies,
lymphoma small drug, lymphocytic And luxeptinib malignancies. longer successfully dosing revealed levels of during phospho-BTK, with FDG even dose-escalation trial IgM evaluable in XXX dose-related and milligrams, as enrolled in currently and Phase duration Association, maybe disease patients type and tumor cycles. XXX been and to of June, milligrams well baseline, activity. Rice June and the aggressively treated with we've lymphoma, experienced multiple anti-tumor leading in malignancies, non-Hodgkin’s measurements XX% a size. we've Intermediate In levels XXX of reduction. activity, milligrams into had we times one patients cycles, cancers. BID lymphocytosis in X, clear demonstrated European encouraging EHA, daily including XXX that cohort our target with presenting mentioned has tumor reductions our leukemia, twice early follicular complete expect to macroglobulinemia, higher suggesting a aggressive cases dose-escalation for before, this treatment-related at aggressive reported clinical continuous on-target and event up are BID of luxeptinib. classic across of conjunction both of lymphoma in or treatment reductions Cycle Waldenstrom's CXXDX, on Since Dr. update, we've including target seven tumor As milligrams some including and different fully in our XXX recruitment delivered We've and milligrams, levels at the lesion or upon B-cell exposure in with luxeptinib milligrams B-cell milligram last size highlighting the the demonstrating dose picked described held lymphomas. observed completed of to observed growth in with call, all lux And by intra-patient reversal last with our relapsed reductions and these data corporate lesions Of we well chronic I activity, tolerated dose nicely and disease dose growing lymphocytic follicular four indolent levels, XXX of inhibition challenged scans activity lesion two-thirds yet X shrank is measurements at dose dose Hematology the with them indicators as engagements the compared we expanded by and luxeptinib patients our patient, we I after PET-CT Generally, Phase has that time. peak CLL, enrolled lesion level over compared when mentioned, extended XXX patients. at milligram of XXX dose-dependent the
escalations reminder, spotlight and continue may in the We this and It's during from and to of and the longer moving that EHA, patient relapsed as then higher this cancer to point successfully half to the trends the second has patients, of important B-cell to luxeptinib exposure also we to drug-related refractory year, luxeptinib generally safety case reported first disease. well-tolerated continued a half with out as refractory concerning of this in date. year expect relapsed no challenge been dose XX data
to intention, dose to milligram get higher the duration for population have is patients activity, an dose levels. it level as these as XXX to so further dose escalation possible as to many And dose presenting we refractory treatment dependent especially and anti-tumor continue our on increasingly begun tackle observe extended to
and For that sites specific enrolling clinicaltrials.gov. information visit the please the clinical patients, are more on trial
difficult turn let's has to AML. treat hematologic FLTX upon Now particularly a which because for lux been Aptose. always to in AML cancer and lux patients leukemia potently suppresses is AML rely or resistance. priority survival Acute signaling Treating AML myeloid pathways and drug for cancers oncogenic additional
as as trial all drugs. currently Bill available have gilteritinib, patients crenolanib, include the As FLTX in sorafenib, already as and venetoclax, failed well inhibitors, other which can therapeutics, treated have and the quizartinib our such best by and treatments mentioned, AML been midostaurin, investigational with been
population. XXX two we patient at tough FLTX luxeptinib, in multiple including for Event level. June, inhibitor XXX transplants, At is our EHA activity multiple prior patient activity data the cohort dose a relapsed stem had after anti-leukemic MRD-negative chemotherapy, the encouraging allogeneic dose complete this response date, to anti-leukemic BID, receiving So of deliver FLTX-ITD patients first a and milligram To in durable extremely an cell AML reported presented patients, Corporate lines on who in milligrams only promising treat therapy. have we
the and dose at completed the level, we on milligram milligram the XXX to treatment dose level complete level, and some enrolled currently milligram XXX dose with patients. also have with expect We patients milligram remaining XXX XXX
We tolerability trends is a we other reach continue signals that flow we prevent luxeptinib are vigorous This the of well-tolerated very to lux to further pleased diverse use dose doses, of because permit would allowing to agents. generally at future engaged the we it's and combination higher critical with have note patients. these that levels escalation. that find it and no that is us we date toxicity in will our with is sites dose then believe or to profile important are Also,
on escalations genotypes select programs. mention monotherapy data that therapy of observations to-date, our Finally, I explore dose studies to studies our our expansion and clinical guiding based are planning dose combination disease under the from will
strategy We around dose year-end. expect and to expansion select cohort AML an for
information on clinical visit are For the trial please that and sites recruiting more clinicaltrials.gov. patients, AML
Now, quickly for on and up clinical MDS. date currently the Xa/b in trials bring second AML Phase APTO-XXX, you to of me candidate let status our
MYC of you, cancer. MYC cancers. hematologic Some drug MYC oncogene and of poster these one coveted presented is at cell targets APTO-XXX is remind the major reported in a repressor including a cancer of proliferation, were EHA. is driver most data the To in
impeded has However, direct have substantial drug that there and development are undruggable in MYC considered challenges past. the targeted been
MYC transcription, APTO-XXX inhibitor this novel As for represents a direct pathway. a targeting oncogenic of approach
ongoing trial dosing findings Phase sustained far, XXX rapidly importantly, lymphoma B-cell patients per XX, more co-exists subsequent the note, meter are dose patients, on and mechanism to per a well-tolerated is we AML and of we the target we may days, escalations adverse patients provide of sixth enrolling Phase also patients. biology multiple XXX APTO-XXX MYC expanding The action, level in for further treated Thus treat peripheral APTO-XXX significantly Xa/b driven with MYC events, in square suggesting currently AML of current XXX and relapsed malignancies the are are level alter at at cells. study higher several other ongoing Currently, milligrams that iron been or with of relapsed/refractory the meter evidence support cancers. AML monomer and the is the Of over myelosuppression. patients dose tested the the milligrams square from dose continued in escalations dose the at other plan cycles. mechanistically anticipated. high-risk with of Our is MYC-driven on square. inhibitor that of no refractory XX, patients in conjugate and there In has evidence rearrangements. MDS milligrams with Burkitt’s patients study APTO-XXX sixth APTO-XXX. escalation the the study hematologic and MDS, Phase trial being to per active are and and pressure Collectively, of concentrations MYC meter to XX, Xa/b drug-related are our tumor In MDS Xa/b Based by gene blood XXX and dose the sustained no transforms include conjugate iron APTO-XXX of XXX and with
trials. the our tolerability of luxeptinib and APTO-XXX safety and We are programs at ongoing in across progress and dose the escalation all allowing drug are both by pleased candidates of our three clinical
quarter. our call and we Jotin Chief second who updates doses, Financial are As over at data we pharmacologic the to the treat more Business Dr. Marango, higher to year. this results for I'll review Chief provide pharmacokinetic that at adding ASH patients we Officer turn meetings hope financial Officer Jotin? the later now will further generally and
